Nektar Therapeutics

NASDAQ: NKTR · Real-Time Price · USD
27.24
0.55 (2.06%)
At close: Aug 15, 2025, 3:59 PM
27.00
-0.88%
After-hours: Aug 15, 2025, 05:03 PM EDT

Nektar Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
98.43M 90.12M 92.06M 101.91M
Cost of Revenue
30.69M 36.64M 21.64M 24.9M
Gross Profit
67.74M 53.48M 70.42M 77.01M
Operating Income
-105.2M -137.43M -240.24M -446.1M
Interest Income
14.5M 19.01M 6.78M 2.57M
Pretax Income
-119.2M -276.26M -364.98M -523.28M
Net Income
-118.96M -276.06M -368.2M -523.84M
Selling & General & Admin
76.75M 77.42M 92.33M 122.84M
Research & Development
120.91M 114.16M 218.32M 400.27M
Other Expenses
-24.72M -676K n/a n/a
Operating Expenses
172.94M 190.9M 310.66M 523.11M
Interest Expense
28.11M 25.33M 28.91M 47.31M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
203.63M 227.55M 332.29M 548.01M
Income Tax Expense
-239K -200K 3.21M 557K
Shares Outstanding (Basic)
13.71M 12.67M 12.48M 12.22M
Shares Outstanding (Diluted)
13.71M 12.67M 12.48M 12.22M
EPS (Basic)
-8.68 -21.79 -29.51 -42.87
EPS (Diluted)
-8.68 -21.79 -29.51 -42.87
EBITDA
-86.7M -243.11M -323.87M -462.97M
EBIT
-91.09M -250.92M -336.07M -475.97M
Depreciation & Amortization
4.39M 7.82M 12.2M 13M